[INQ. NO. 2501E02] MVITRO Co., Ltd., a medical device company based on laser technology, recently announced that it was selected as a ‘Featured Exhibitor’ in the digital health sector at the world’s largest consumer electronics exhibition, CES 2025.
MVITRO participated in CES by introducing ORTIV, a painless laser monitor for blood collection and blood sugar, which recently received sale approval from the U.S. Food and Drug Administration (FDA).
ORTIV is a medical device that uses lasers instead of disposable needles to painlessly collect blood and measure blood sugar levels. It has reduced the pain of the blood collection process to a painless level, and is receiving attention not only in Korea but also in the United States, Japan, and Europe.
For the U.S. market, ASI, which supplies medical equipment to blood transfusion institutions, signed a contract with MVITRO for sale of ORTIV. And for the Korean market, a pharmaceutical company is preparing to exclusively distribute ORTIV. In addition, it is reported that Toyobo, a Japanese diagnostic enzyme manufacturer, requested MVITRO to develop a painless laser for diagnosing various diseases.

A spokesperson for the company explained, “Since last year, we have participated in CES with a prototype of ORTIV and met many buyers who showed great interest in our painless laser blood collection technology,” adding “We currently have over 25 confirmed interviews, and since FDA approval for ORTIV was recently achieved, we expect that many of them will lead to actual contracts this time.”
MVITRO expects ORTIV to receive approval from Korea’s Ministry of Food and Drug Safety in the first quarter of this year. It plans to begin domestic sales of ORTIV as soon as the approval process is completed.
MVITRO is also planning to enter the European market in the second half of this year. MVITRO is developing a hemoglobin measuring device with the U.S. blood donation organization, Vitalant, by using the laser technology incorporated in ORTIV. Based on this reference, MVITRO unveiled its plans to enter markets such as China and Southeast Asia in the future.
“We developed ORTIV by recognizing the stress felt by patients when having blood collected. We will contribute to overcoming blood collection trauma through ORTIV, which has significantly reduced blood collection discomfort,” explained the company’s CEO.

 
korean-electronics.com | Blog Magazine of korean electronics, brands and Goods